|Bid||26.14 x 1000|
|Ask||26.06 x 900|
|Day's Range||25.90 - 26.78|
|52 Week Range||17.80 - 45.02|
|Beta (3Y Monthly)||3.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 4, 2019 - Mar 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.71|
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the journal Nature Medicine published the comprehensive, pre-clinical data demonstrating the pharmacology and specificity of EDIT-101, an experimental, CRISPR genome editing medicine being investigated for the treatment of Leber congenital amaurosis 10 (LCA10), a genetically-driven form of blindness. “We are thrilled Nature Medicine published our paper sharing the comprehensive set of pre-clinical data for EDIT-101 and our approach to creating CRISPR-based genome editing medicines,” said Charles Albright, Ph.D., Chief Scientific Officer, Editas Medicine. “The research presented in this important manuscript provided the foundation for our recently accepted Investigational New Drug (IND) application for EDIT-101 to treat LCA10, bringing us closer to the clinic and our goal of realizing the full potential of genome editing.
Editas Medicine (EDIT) closed at $26.03 in the latest trading session, marking a -0.69% move from the prior day.
The future of medicine involves the precise engineering of human cells. Turns out, that future may not include that promising CRISPR technique.
NEW YORK, NY / ACCESSWIRE / January 15, 2019 / Wall Street extended losses on Monday as concerns of a global economic slowdown were reignited on weaker-than-expected economic data from China. In December, ...
Editas Medicine (EDIT) closed at $26.20 in the latest trading session, marking a -0.8% move from the prior day.
Pharmaceutical giants like Bayer and Novartis have dipped their toes into gene editing through collaborations, while others are adopting it in their own laboratories.
Radius (RDUS) exceeds its 2018 financial guidance, with full-year U.S. net sales of its lead drug Tymlos surpassing the upper range of $95-$98 million.
Editas Medicine, YY, Intel, Advanced Micro Devices and NVIDIA highlighted as Zacks Bull and Bear of the Day
Aerie (AERI) announces encouraging top-line results from its pilot phase II study of netarsudil ophthalmic solution in a Japan.
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.
In a presentation to investors on Wednesday, January 9, 2019, at 9:00 a.m. PST at the 37th Annual J.P. Morgan Healthcare Conference, Editas Medicine, Inc. (EDIT) President and CEO Katrine Bosley will discuss the Company’s plans to initiate patient screening and patient dosing for EDIT-101. Additionally, she will outline progress in the Company’s program for the treatment of sickle cell disease, including data that support opportunities to develop best-in-class, durable medicines for hemoglobinopathies. Ms. Bosley will also detail the Company’s progress on “EM22,” the Company’s long-range goals through the year 2022 and vision for advancing Editas Medicine as a leading genome editing company, including sharing details on advancements in its ocular and engineered cell medicine programs.
Jazz (JAZZ) collaborates with Codiak for research, development and commercialization of exosome therapeutics to treat cancer.
Crispr Therapeutics popped Friday after the FDA said it would expedite review of its Vertex Pharmaceuticals-partnered gene-editing sickle cell disease treatment.
Novo Nordisk (NVO) has a strong presence in the Diabetes Care market and boasts a strong pipeline, with focus on therapeutic proteins within insulin.
Sarepta (SRPT) inks long-term strategic deal with Aldevron for the supply of plasmid DNA to fulfill the former's needs for its gene-therapy clinical trials and commercial supply.
CAMBRIDGE, Mass., Jan. 02, 2019 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a.
Editas Medicine president and CEO Katrine Bosley discusses her company's gene editing technology and the future of medicine.
Even though biotech markets are “down big this year,” Managing Director Mitchell Ng of Thessalus Capital says that there are “specific industries within the healthcare sector that are very promising,” such as gene editing companies. Yahoo Finance’s Alexis Christoforous speaks to him about the future for biotech in 2019.